Having trouble accessing articles? Reset your cache.

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas.

The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It is an enteric formulation of budesonide that down-regulates

Read the full 421 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE